Moreover, in NAFLD patients, serum CCN2 was higher than in healthy controls, allowed discrimination between patients with no, mild or advanced fibrosis, and was an independent predictor of fibrosis stage [71]. The gene discussed is CCN2; the disease is metabolic dysfunction-associated steatotic liver disease.